Observational study on wearable biosensors and machine learning-based remote monitoring of COVID-19 patients.

Journal: Scientific reports
PMID:

Abstract

Patients infected with SARS-CoV-2 may deteriorate rapidly and therefore continuous monitoring is necessary. We conducted an observational study involving patients with mild COVID-19 to explore the potentials of wearable biosensors and machine learning-based analysis of physiology parameters to detect clinical deterioration. Thirty-four patients (median age: 32 years; male: 52.9%) with mild COVID-19 from Queen Mary Hospital were recruited. The mean National Early Warning Score 2 (NEWS2) were 0.59 ± 0.7. 1231 manual measurement of physiology parameters were performed during hospital stay (median 15 days). Physiology parameters obtained from wearable biosensors correlated well with manual measurement including pulse rate (r = 0.96, p < 0.0001) and oxygen saturation (r = 0.87, p < 0.0001). A machine learning-derived index reflecting overall health status, Biovitals Index (BI), was generated by autonomous analysis of physiology parameters, symptoms, and other medical data. Daily BI was linearly associated with respiratory tract viral load (p < 0.0001) and NEWS2 (r = 0.75, p < 0.001). BI was superior to NEWS2 in predicting clinical worsening events (sensitivity 94.1% and specificity 88.9%) and prolonged hospitalization (sensitivity 66.7% and specificity 72.7%). Wearable biosensors coupled with machine learning-derived health index allowed automated detection of clinical deterioration.

Authors

  • Ka-Chun Un
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Chun-Ka Wong
    Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
  • Yuk-Ming Lau
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Jeffrey Chun-Yin Lee
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Frankie Chor-Cheung Tam
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Wing-Hon Lai
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Yee-Man Lau
    Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Hao Chen
    The First School of Medicine, Wenzhou Medical University, Wenzhou, China.
  • Sandi Wibowo
  • Xiaozhu Zhang
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Minghao Yan
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Esther Wu
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Soon-Chee Chan
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Sze-Ming Lee
    Harmony Medical Inc, Hong Kong SAR, China.
  • Augustine Chow
    Harmony Medical Inc, Hong Kong SAR, China.
  • Raymond Cheuk-Fung Tong
    Harmony Medical Inc, Hong Kong SAR, China.
  • Maulik D Majmudar
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Kuldeep Singh Rajput
  • Ivan Fan-Ngai Hung
    Infectious Diseases Division, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Chung-Wah Siu
    Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong.